Elon Musk Says Optimus Production Will Be 'Extremely Slow' in the Beginning: 'This is Not Like Making a Car' finance.yahoo.com/technology…

$QTEX: April 6, 2026. QTREX Quantum acquired the AME platform from Nano Dimension. July 6, 2026. Exactly 91 days later, that same platform is running inside a U.S. Government national security lab. globenewswire.com/news-relea… The lab is one of the most prominent U.S. government research environments focused on national security, applying science and engineering to identify, deter, defeat, and mitigate threats to the U.S. and its allies. Its quantum computing programs move technology from experimental research toward practical engineered systems: fabrication, control technologies, modeling, and real-world testing. QTREX's AME system provides the infrastructure layer that supports that transition. The 91-day arc is worth tracing: acquisition, government grant for the world's first native RF dielectric material, Fortune 500 purchase order, 97% yield at a major U.S. interconnect manufacturer, a cryogenic chip carrier built for one of the world's largest quantum computing companies, and now federal operational deployment. Each step has been externally verified by a named or described third party. The Q2 2026 financial results will be the next major disclosure window, with management having announced personal share purchases of up to 2,000,000 ordinary shares set to begin after that report. Disclosure: This content is not financial or investment advice. QTREX Quantum Ltd. is a paid subscriber to Wall Street Wire's coverage and distribution platform. Full disclosure: wallstwire.ai/disclosures

$QUCY just named a number that most defense startups never get specific about. Can a 50,000 square foot facility in Bridgeport, Connecticut actually produce 100,000 drones per year? That is the question CEO David Lazar answered on July 6, 2026. His answer: "100,000 drones per year, from a single facility we own and operate is the target. Bridgeport is not a concept. It is a production address." globenewswire.com/news-relea… The production model is two parallel automated assembly lines. One runs kamikaze one-way attack platforms. The other runs autonomous interceptor systems. Five total product categories: Kamikaze, Interceptor, Surveillance, VTOL, and the long-range Phantom 950 introduced four days earlier. What makes this more than a press release projection is the facility infrastructure already in place. The $3.2 million acquisition of 38 Union Avenue, Bridgeport included stamping presses, CNC machining centers, lathes, surface grinders, and overhead crane systems. A 20,780 square foot primary production floor. Quantum Drones Corporation holds all of it. The DoD FY2027 budget allocates roughly $55 billion toward drone and autonomous warfare programs. Executive Order 14307 directed domestic production acceleration as a national security priority. The attritable drone doctrine specifically calls for low-cost, scalable, modular systems. Full production data across both assembly lines is what turns this announcement into a track record. _ Disclosure: This content is not financial or investment advice. Quantum Cyber N.V.. is a paid subscriber to Wall Street Wire's coverage and distribution platform. Full disclosure: wallstwire.ai/disclosures

$QUCY just gave short-sellers one of the most documented rebuttals in recent small-cap defense history. Short-sellers typically target companies with sparse paper trails. Quantum Cyber N.V. today answered every major allegation with SEC filings, signed definitive agreements, patent filings at the U.S. Patent and Trademark Office, a named scientist with a verifiable MIT PhD and active faculty at Drexel, and a CEO whose share transactions are legally constrained by Rule 144 and Section 16 reporting obligations. This company has been executing publicly and rapidly. Over the past several weeks: it signed a definitive agreement to acquire a 50,000-square-foot manufacturing facility in Bridgeport, Connecticut for $3,200,000. It unveiled the Quantum Station command-and-control platform. It introduced the PHANTOM-950 long-range autonomous UAS. It secured exclusive worldwide rights to quantum photonic array technology through a definitive IP License Agreement with Project LightShift. Its balance sheet is debt-free with over $15,000,000 in warrant proceeds received in May 2026. The short-seller chose to attack a company in the middle of rapid, documented buildout. The company has now retained investigative and litigation specialist firms and begun formally assessing damages against a short-seller that was recently sued for $20,000,000 by another Nasdaq company for similar conduct. Next milestones to watch: completion of the Bridgeport, Connecticut manufacturing facility acquisition and the first formal update on litigation proceedings. globenewswire.com/news-relea… _ Disclosure: This content is not financial or investment advice. Quantum Cyber N.V. is a paid subscriber to Wall Street Wire's coverage and distribution platform. Full disclosure: wallstwire.ai/disclosures

$QUCY just gave short-sellers one of the most documented rebuttals in recent small-cap defense history. Short-sellers typically target companies with sparse paper trails. Quantum Cyber N.V. today answered every major allegation with SEC filings, signed definitive agreements, patent filings at the U.S. Patent and Trademark Office, a named scientist with a verifiable MIT PhD and active faculty at Drexel, and a CEO whose share transactions are legally constrained by Rule 144 and Section 16 reporting obligations. This company has been executing publicly and rapidly. Over the past several weeks: it signed a definitive agreement to acquire a 50,000-square-foot manufacturing facility in Bridgeport, Connecticut for $3,200,000. It unveiled the Quantum Station command-and-control platform. It introduced the PHANTOM-950 long-range autonomous UAS. It secured exclusive worldwide rights to quantum photonic array technology through a definitive IP License Agreement with Project LightShift. Its balance sheet is debt-free with over $15,000,000 in warrant proceeds received in May 2026. The short-seller chose to attack a company in the middle of rapid, documented buildout. The company has now retained investigative and litigation specialist firms and begun formally assessing damages against a short-seller that was recently sued for $20,000,000 by another Nasdaq company for similar conduct. Next milestones to watch: completion of the Bridgeport, Connecticut manufacturing facility acquisition and the first formal update on litigation proceedings. globenewswire.com/news-relea… _ Disclosure: This content is not financial or investment advice. Quantum Cyber N.V. is a paid subscriber to Wall Street Wire's coverage and distribution platform. Full disclosure: wallstwire.ai/disclosures

$DUKR named a new CEO on June 11, 2026, with a background that reads differently from most small-cap drone company leadership transitions. Yiftach Kleinman comes from SpearUAV, the Israeli autonomous drone developer he helped scale through international contracts before its late-2025 acquisition by UVision Air. Before SpearUAV, he spent more than a decade at Rafael Advanced Defense Systems: the developer of Iron Dome, David’s Sling, Spike ATGM, and Trophy APS. At Rafael, he served as Deputy General Manager for Subsidiaries, Mergers and Acquisitions, and helped execute what Rafael described as its largest-ever acquisition in a major NATO country. His appointment becomes effective no later than September 8, 2026. benzinga.com/content/6027268… The context matters. Duke Robotics currently earns royalties on Elbit’s global sales of the Bird of Prey, a combat-validated stabilized weapons drone. A new Elbit order was confirmed on June 23, 2026, with deliveries expected later this year. Duke has stated its intent to significantly expand its defense business beyond the existing Elbit collaboration. Kleinman’s direct relationships across the global defense supply chain are central to that stated strategy. Watch for Kleinman’s first official strategic update after his September 8, 2026 start date. That first communication will frame how Duke intends to expand its defense footprint with the capital raised in the May 2026 uplisting. _ Disclosure: This content is not financial or investment advice. Duke Robotics Corp. is a paid subscriber to Wall Street Wire’s coverage and distribution platform. Full disclosure: wallstwire.ai/disclosures

Big pharma's M&A playbook is shifting. Biogen and Lilly just dropped back-to-back mega-deals on the same day, signaling a strategic pivot away from single-drug dependency. Biogen building out immunology. Lilly diversifying beyond GLP-1. When biotech valuations recover, the consolidation wave hits different. $LLY biopharmadive.com/news/bioge…

What does it take to sign two top-10 global enterprises in your first 90 days as a public company? For $SCAI.V, apparently, a product that runs in production. The two deployments are not MOU announcements. They are live systems. A Latin American unit of a global life insurer ranked in the world's top-10 by S&P Global started running SalesCloser's AI voice agents on customer engagement and onboarding workflows on May 5, 2026. A 270-room beachfront resort, part of one of the world's ten largest hotel companies, is using the same platform to automate after-hours room service calls through a direct Oracle Hospitality POS integration. benzinga.com/content/6026946… That traction sits against a balance sheet that is cleaner than most TSXV-listed AI names: $6.46 million in cash at quarter-end, no long-term debt, 70.4% gross margins, and 224% year-over-year revenue growth in Q2. The company also commissioned a dedicated NVIDIA Blackwell-class GPU inference cluster in Canada during May, a move designed to enable custom model fine-tuning on proprietary sales conversation data and unlock regulated industries including financial services, healthcare, and government. The next release in this arc will tell investors whether regulated-industry pipeline is materializing from the NVIDIA compute investment and whether the two enterprise deployments are anchoring into durable ARR. _ Disclosure: This content is not financial or investment advice and is distributed on behalf of SalesCloser Technologies Ltd., a paid subscriber to Wall Street Wire's coverage and distribution platform. Full disclosure: wallstwire.ai/disclosures

Eli Lilly just spent $25B on 10 biotech acquisitions in 2026 alone. That's half of what the entire pharma industry spent combined. The real story? $LLY isn't just riding the obesity wave. They're systematically building a diversified pipeline across oncology, vaccines, neurology, and genetic medicine. When a company with that much cash gets this aggressive on M&A, it signals confidence in their ability to execute at scale. biospace.com/business/lillys…

$PYPD - 60% risk reduction in surgical infections meets market validation. On June 1, 2026, PolyPid completed its NDA submission for D-PLEX₁₀₀ following Phase 3 SHIELD II trial results showing 60% relative risk reduction (p=0.0013) in surgical site infections across 798 abdominal colorectal surgery patients. Three weeks earlier, Eli Lilly validated the entire surgical infection prevention space by paying up to $780 million for LimmaTech Biologics - a Phase 1 vaccine company targeting the same indication. The market math is striking: nearly a billion dollars for early-stage science versus PolyPid's sub-$100M valuation with Phase 3-positive data. tradingview.com/news/finance… D-PLEX₁₀₀'s mechanism addresses a critical gap in current care. While standard IV prophylaxis clears within hours and struggles to reach incision margins where blood flow is disrupted, D-PLEX₁₀₀ anchors to the surgical site for continuous 30-day antibiotic release - exactly the CDC's identified infection window. The regulatory pathway is well-supported with Breakthrough Therapy, Fast Track, and QIDP designations, plus a $4.3 million PDUFA fee waiver granted in March 2026. Management confirms U.S. commercial partnership discussions are in late stages, with former BD surgery executive Brooke Story appointed as Chairman in December 2025. Next inflection frame: FDA acceptance of the NDA filing will establish the formal review timeline leading to the anticipated Q1 2027 PDUFA target action date. _ Disclosure: This content is not financial or investment advice. PolyPid Ltd. is a paid subscriber to Wall Street Wire's coverage and distribution platform. Full disclosure: wallstwire.ai/disclosures

EU Court Seals €4.1B Google Android Fine, Triggering Damages Threat for Rivals techtimes.com/articles/31958…

The jobs report just rewrote the playbook. 57K hires vs 115K expected should hurt growth stocks, right? Instead, the Dow hit all-time highs while Nasdaq tanked 0.8%. Chip stocks got decimated (Sandisk down 14%). This isn't a crash, it's a rotation. Weak labor data = lower rate hike odds = value's moment. The market's telling us something about where it thinks growth is headed. wsj.com/livecoverage/june-jo…

$MDWD: The defense trade has a blind spot. Three years of conflict have sent missile makers and drone companies sharply higher. The product governments need when the casualties start arriving has barely registered with retail investors. NexoBrid is the only FDA-approved enzymatic agent for severe burn debridement. It does what surgery does, but without the operating room, without the anesthesiologist, without the specialist burn surgeon. That matters in a mass-casualty scenario where none of those resources are available. Real-world U.S. data published in the Journal of Burn Care and Research from 239 patients showed rapid eschar removal and a low rate of surgical excision. markets.businessinsider.com/… In April 2026, Vericel was awarded a 10-year BARDA contract up to $197 million for NexoBrid. The base period is $35 million. The contract covers Stockpile procurement, vendor-managed inventory, blast trauma indication development, and next-generation formulation work. New endorsements from Japanese and U.K. national guidelines add to existing recommendations from WHO, Italy, Spain, Romania, and Poland, reflecting growing global clinical validation. The data point that determines EscharEx's commercial path is the Phase III VALUE interim analysis, expected in Q1 2027. It sets the final patient count and the regulatory filing timeline for the chronic wound debridement market. _ Disclosure: This content is not financial or investment advice. MediWound Ltd. is a paid subscriber to Wall Street Wire's coverage and distribution platform. Full disclosure: wallstwire.ai/disclosures

This morning, $QUCY unveiled PHANTOM-950: a long-range autonomous UAS in development for missions of up to 950 kilometers. What does a defense company do after locking down a binding $3.2 million manufacturing facility acquisition and reaching a debt-free balance sheet? It introduces the aircraft it plans to manufacture there. The PHANTOM-950 is a blended-wing, multi-stage propulsion platform designed for extended-range autonomous operations: target altitude 18,000 meters, payload capacity up to 10 kilograms, modular mission configurations covering logistics, ISR, communications relay, electronic warfare, humanitarian support, and one-way profiles. The design supports reconfigurability rather than a fixed mission type. No prototype has been built or tested, and published specifications are internal design objectives pending independent validation. The building blocks of the broader System-of-Systems architecture are real and in place: Quantum Station (the C2 platform, unveiled June 23), the quantum photonic array antenna IP license (executed through Project LightShift, June 11), and the Bridgeport, Connecticut manufacturing facility (definitive agreements signed June 29 for a 50,000-square-foot facility at $3.2 million aggregate consideration). PHANTOM-950 adds the long-range airframe to that stack. The read that matters here: whether Quantum Cyber begins prototype development for PHANTOM-950. A working prototype transitions the platform from architecture building to proof-of-performance and closes the gap between a well-constructed strategic narrative and a deliverable system concept. globenewswire.com/news-relea… _ Disclosure: This content is not financial or investment advice. Quantum Cyber N.V. is a paid subscriber to Wall Street Wire's coverage and distribution platform. Full disclosure: wallstwire.ai/disclosures

Ashton Kutcher leaving Sound Ventures to launch new VC firm with Morgan Beller techcrunch.com/2026/07/01/as…

Pharma's patent cliff is real and it's driving a spending spree. $134B in biotech M&A in just 6 months of 2026, already crushing last year's total. When blockbusters like Keytruda ($29.5B) face expiration, you gotta fill the pipeline. Big Pharma isn't hunting for innovation anymore, they're hunting for survival. statnews.com/2026/06/22/phar…

$QTEX just inverted the standard design logic for cryogenic quantum interconnects, and filed a provisional patent to back it up. globenewswire.com/news-relea… The standard approach to cryogenic signal lines in quantum systems is to choose a conductor material with acceptable electrical properties, then manage the thermal consequences using anchors, attenuators, and filtering stages. The material's thermal behavior is treated as fixed. The system design works around it. QTREX filed a provisional patent today for an architecture that does the opposite. The Company applies the Wiedemann-Franz Law, which describes the physical relationship between electrical and thermal conductivity in metallic conductors, at the materials-formulation stage. That means before manufacturing begins, the conductivity profile of the material is set to meet a specific thermal target. The material is engineered to carry the signal and resist the heat as a single designed outcome. This is possible because the Company owns the full process: materials chemistry, additive manufacturing, and finished component end to end. The CEO stated today: "Our ability to dictate material properties from the chemical formulation through to the final component gives us a unique competitive advantage in the quantum sector." That dictation is the basis of the patent. As quantum systems move from hundreds to thousands of qubits, thermal load at the millikelvin stage becomes the binding physical constraint. Whether this controlled-conductivity architecture can deliver at that scale is the question that determines how much of that infrastructure challenge QTREX's platform can address. _ Disclosure: This content is not financial or investment advice. QTREX Quantum Ltd. is a paid subscriber to Wall Street Wire's coverage and distribution platform. Full disclosure: wallstwire.ai/disclosures

Nvidia competitor Etched hits $5B valuation, $1B in sales for AI chip techcrunch.com/2026/06/30/nv…

The paradox nobody wants to admit: earnings are crushing it, but valuations are screaming bubble. BofA's Bubble Risk Indicator is flashing 0.91 for semiconductors. The real question isn't whether AI spending is justified, it's whether the returns will ever materialize. Strong earnings can mask stretched valuations for only so long. reuters.com/legal/transactio…

$DUKR: Most defense microcaps never make it past a letter of intent. Duke Robotics has a combat-confirmed weapons drone with $9.2 million in fresh Nasdaq capital and a new Elbit order confirmed June 23. benzinga.com/content/6018782… Elbit Systems Land Ltd. has received a new purchase order for the Bird of Prey stabilized weapons drone system. Deliveries are expected in H2 2026. Duke Robotics earns royalties under the long-term collaboration agreement, recognized when Elbit delivers the systems and receives the related proceeds. The Bird of Prey is built on Duke's proprietary stabilization technology, addressing a long-standing technical challenge for weaponized drone platforms. It has been confirmed in IDF operational use. Elbit has broad international marketing and distribution reach to drive demand. When the H2 2026 deliveries close and Elbit confirms receipt of proceeds, that is the signal that royalty revenue recognition for Duke is not a one-time event but a repeating cadence. _ Disclosure: This content is not financial or investment advice. Duke Robotics Corp. is a paid subscriber to Wall Street Wire's coverage and distribution platform. Full disclosure: wallstwire.ai/disclosures